Navigation Links
Pacira Pharmaceuticals Highlights Additional Safety Data on EXPAREL™ for Postsurgical Pain Relief at 2011 American Academy of Orthopaedic Surgeons Annual Meeting
Date:2/15/2011

significantly less opioids were consumed
  • The median time to first use of opioid rescue medication was 7.2 hours for patients treated with EXPAREL compared with 4.3 hours for patients treated with placebo (p<0.0001)
  • A larger percentage of patients treated with EXPAREL avoided any opioid rescue medication during the first 24 hours after surgery compared to placebo (7% vs.1%; p<0.05)
  • EXPAREL was well tolerated in patients who received postsurgical treatment for pain following bunionectomy
  • There were no statistically significant differences between treatment groups in wound assessments (erythema, drainage, edema, and in duration)
  • No patients demonstrated any evidence of malunion or non-union. Follow-up radiographs and documentation of wound healing were collected for 82% of patients four to six weeks post bunionectomy procedures
  • The incidence of adverse events was lower in the EXPAREL group (60%) than in the placebo group (68%); the most common events in both groups were nausea, vomiting, and dizziness

  • "EXPAREL addresses an unmet need in postsurgical pain control, which is the need for a longer-lasting, non-opioid analgesic," said David Stack, president and chief executive officer, Pacira Pharmaceuticals, Inc. "We believe these findings along with previously reported efficacy data continue to differentiate EXPAREL."

    "Based upon the findings of this Phase 3 study, we believe Pacira's DepoFoam® technology enables EXPAREL to safely and effectively extend the duration of pain relief by more than 67% compared with placebo," added Stephen Daniels, D.O., primary study investigator and executive medical director, Premier Research Group Limited, Austin, Texas. "EXPAREL has the potential to be the first FDA-approved long-acting bupivacaine analgesic and should be well positioned to support a standard postsurgical treatment regimen. In addition, EXPAREL's ease-of-use should allow medical professionals
    '/>"/>

    SOURCE Pacira Pharmaceuticals, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5

    Related medicine technology :

    1. Pacira Pharmaceuticals, Inc. Announces Pricing of Its Initial Public Offering
    2. Pacira Pharmaceuticals Presents New Data from EXPAREL Phase 3 Study at Orthopaedic Research Societys 57th Annual Meeting
    3. Pacira Pharmaceuticals Announces FDA Acceptance of EXPAREL™ New Drug Application for Pain Management
    4. Phase III Studies of EXPAREL(TM) (DepoBupivacaine) from Pacira Complete Enrollment
    5. Positive Phase II Study of Paciras EXPAREL(TM) (DepoBupivacaine) in Hernia Repair Presented at the Postgraduate Assembly in Anesthesiology (PGA)
    6. Positive Phase II Study of Paciras EXPAREL(TM) (DepoBupivacaine) in Total Knee Arthroplasty Presented at International College of Surgeons World Congress
    7. ADVENTRX Pharmaceuticals Provides Update on ANX-514
    8. Valeant Pharmaceuticals to Announce 2010 Fourth Quarter and Full Year Results on February 24, 2011
    9. Conatus Pharmaceuticals Completes $20 Million Series B Private Placement Financing
    10. Optimer Pharmaceuticals, Inc. Prices Public Offering of Common Stock
    11. AcelRx Pharmaceuticals Announces Pricing of Its Initial Public Offering
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:9/17/2014)... , Sept. 17, 2014  Neuraltus Pharmaceuticals, Inc. ... Phase 2 clinical program of NP001 for the treatment ... disease) are being highlighted today in an oral ... Research Group , being held in Bloomington, ... post hoc  analysis, administration of a high dose of ...
    (Date:9/17/2014)... and MILL VALLEY, Calif. ... Sarcoma Alliance today announced a partnership in the ... will sponsor the Sarcoma Alliance Suzanne Renee Leider ... program offers financial assistance to reimburse sarcoma patients ... opinion from a sarcoma specialist. Scientific literature reinforces ...
    (Date:9/17/2014)... Sept. 17, 2014  Trovagene, Inc., (NASDAQ:   TROV) ... Alberto Bardelli , Ph.D., has joined the Company,s ... to identify mutations in the kinase genes that are ... is at the Department of Oncology, Torino Medical School, ... . "Alberto,s work in cancer ...
    Breaking Medicine Technology:Neuraltus Pharmaceuticals' ALS Treatment Candidate, NP001, Highlighted at ALS Research Group Summit 2Neuraltus Pharmaceuticals' ALS Treatment Candidate, NP001, Highlighted at ALS Research Group Summit 3Champions Oncology Partners with Sarcoma Alliance to Bring Personalized Treatment Options to Sarcoma Patients 2Champions Oncology Partners with Sarcoma Alliance to Bring Personalized Treatment Options to Sarcoma Patients 3Cancer Geneticist, Alberto Bardelli, Ph.D., Joins Trovagene's Scientific Advisory Board 2Cancer Geneticist, Alberto Bardelli, Ph.D., Joins Trovagene's Scientific Advisory Board 3
    ... , , SANTA FE SPRINGS, Calif., ... in the design and manufacturing of superior air cleaning products, ... year,s exclusive Top 10 Products for Parents listing by Parent ... I look for the safest products available for my children," ...
    ... , , , ... Obama Administration rejected a plan to allow the wholesale reimportation ... take on the drug industry and secure cheaper prescription for ... percent more for drugs than people in Canada, Australia, the ...
    Cached Medicine Technology:IQAir HealthPro Plus Selected as a Top 10 Product for Parents 2IQAir HealthPro Plus Selected as a Top 10 Product for Parents 3Obama Plan Buckles Under Pharma Lobby; Plan to Import Low-Cost Medicines Derails 2Obama Plan Buckles Under Pharma Lobby; Plan to Import Low-Cost Medicines Derails 3
    (Date:9/17/2014)... New York, N.Y. (PRWEB) September 17, 2014 ... for fans taking part in the fitness industry’s most ... in Las Vegas, NV. Two fans will each take ... fully loaded with Neon Sport supplements and gear. Fitmark ... booth during the Olympia Expo, September 19-20th. , ...
    (Date:9/17/2014)... September 17, 2014 According to ... ), the leading global authority in medical device ... and regeneration market is expected to exceed ... into breast reconstruction, hernia repair, dural repair, vaginal ... and dental soft tissue regeneration. , Approximately ...
    (Date:9/17/2014)... Kamut International is pleased to announce ... in Michael Angelo’s new “Made With Organic” ready-made, frozen ... lasagna ready made, frozen meal. Michael Angelo’s products feature ... new products align well with Kamut International’s mission to ... wheat must be grown certified organic. , The new ...
    (Date:9/17/2014)... PA (PRWEB) September 17, 2014 ... and increase efficiency. Today, Pharmacy Healthcare Solutions, a ... a web-based analysis and forecasting tool that enables ... maximizing the impact of medications on improved patient ... Reporting uses pharmacy purchase data to identify areas ...
    (Date:9/17/2014)... HealthDay Reporter , TUESDAY, ... Americans dying from accidental overdoses of narcotic painkillers jumped ... Tuesday. Deaths from overdoses of drugs such as ... per 100,000 people to 5.4 per 100,000, according ... That means about 3,000 people died in 1999 ...
    Breaking Medicine News(10 mins):Health News:Electrifying Sports Nutrition Brand, Neon Sport, Pairs with Global Fitness Bag & Luggage Brand, Fitmark Bags, for an Exclusive Giveaway at Olympia Expo, This Weekend 2Health News:Bilateral Breast Reconstruction Rate in the U.S. is one of the Highest in the World 2Health News:Bilateral Breast Reconstruction Rate in the U.S. is one of the Highest in the World 3Health News:KAMUT® Brand Wheat Delivers a High Quality Ingredient and Authentic Italian Taste for Michael Angelo’s New Ready-Made Meals featuring Organic Ingredients 2Health News:Pharmacy Healthcare Solutions Launches TARxGET™ Reporting 2Health News:Pharmacy Healthcare Solutions Launches TARxGET™ Reporting 3Health News:Deaths From Narcotic Painkillers Quadrupled in Past Decade: CDC 2Health News:Deaths From Narcotic Painkillers Quadrupled in Past Decade: CDC 3
    ... ... for Haiti,s Earthquake Victims, New Campaign Seeks Participants in Healing Service for Chile on ... ... and Master Zhi Gang Sha and the Institute of Soul Healing and Enlightenment, shortly after ...
    ... ... ... ... ...
    ... ... ... , ... , , ...
    ... ... ... ... ...
    ... of the major cancers in Northeast Thailand. This cancer ... mortality rates. Overexpression of Met, a hepatocyte growth factor ... is correlated with progression of this type of cancer. ... cell scattering, invasion and proliferation. Although a number of ...
    ... to see the human brain at work, a new generation ... appeal while it is still being designed, according to a ... University. So-called "neuromarketing" takes the tools of modern brain ... somewhat abstract likes and dislikes of customer decision-making. Though ...
    Cached Medicine News:Health News:Master Zhi Gang Sha Dedicates Soul Healing Blessings for Humanity Service to Chile's Earthquake Victims 2Health News:New York State Adopts Universal Provider Datasource to Reduce Administrative Costs for Medicaid 2Health News:New York State Adopts Universal Provider Datasource to Reduce Administrative Costs for Medicaid 3Health News:New York State Adopts Universal Provider Datasource to Reduce Administrative Costs for Medicaid 4Health News:New York State Adopts Universal Provider Datasource to Reduce Administrative Costs for Medicaid 5Health News:Studies Detail Possible Benefits of omega-3 Fatty Acids for Dogs With Arthritis 2Health News:Studies Detail Possible Benefits of omega-3 Fatty Acids for Dogs With Arthritis 3Health News:Studies Detail Possible Benefits of omega-3 Fatty Acids for Dogs With Arthritis 4Health News:Community Pharmacists Rise to Meet Winter Weather Challenges, Survey Finds 2Health News:Community Pharmacists Rise to Meet Winter Weather Challenges, Survey Finds 3Health News:Community Pharmacists Rise to Meet Winter Weather Challenges, Survey Finds 4Health News:Community Pharmacists Rise to Meet Winter Weather Challenges, Survey Finds 5Health News:Different signaling pathways of cholangiocarcinoma 2
    ... The ThromCat™ System is the first thrombectomy ... strength and simplicity for the full range ... Heliflex™ technology, the new ThromCat™ System flushes, ... of 700 mmHg and incorporates advanced vessel-wall ...
    ... telescoping plate design integrates the ... and vertebral column spacer. This ... need for supplemental fixation while ... bone graft to be delivered ...
    ... Tendril ST leads are ... leads, designed to bring ... and flexibility to you ... pre-formed "J leads are ...
    The MYO-VAD is a novel cardiac support system with unique, life-saving features....
    Medicine Products: